tbuckley/cabot-search huggingface dataset:
Germline-Somatic Interactions in Myelofibrosis Susceptibility
Authors: Derek W Brown, Youjin Wang, Andrew St. Martin, Stephen R. Spellman, Shu-Hong Lin, Olivia Lee, Alyssa Klein, Tongwu Zhang, Weiyin Zhou, Kristine Jones, Amy Hutchinson, Jia Liu, Bin Zhu, Casey Dagnall, Sairah Khan, Maryam Rafati, Tao Wang, H. Joachim Deeg, Vikas Gupta, Stephanie J. Lee, Meredith Yeager, Sharon A. Savage, Wael Saber, Shahinaz Gadalla, Mitchell Machiela
Journal: Blood (2021)
Asia-Pacific Consensus Statement on integrated 24-hour activity guidelines for children and adolescents
Authors: Benny Kai Guo Loo, Anthony David Okely, Aman Pulungan, Muhammad Yazid Jalaludin
Journal: British Journal of Sports Medicine (2021)

Non-communicable diseases (NCDs) constitute a significant public health challenge and pose a great burden on health and social systems throughout the world. The Asia-Pacific region is in a vulnerable position as the prevalence of NCDs will inevitably increase with rapid socioeconomic transitions; yet it is ill prepared for this public health challenge as Asian children are among the most physically inactive in the world. Aligned with the WHO's global strategy to control NCDs via preventive measures and health promotion policies, representatives from the Asia-Pacific region came together to develop consensus statement on integrated 24-hour activity guidelines for children and adolescents. These guidelines apply to children and adolescents, aged 5-18 years, in the Asia-Pacific region, regardless of gender, cultural background or socioeconomic status. These guidelines aim to provide the latest evidence-based recommendations, taking a holistic approach to lifestyle activities and adopting a practical perspective by framing these activities within a 24-hour period. Eating and dietary elements were incorporated as they closely influence the energy balance of the movement behaviours and vice versa. By investing in the younger generations through advocacy for healthier lifestyles, we aim to reduce the burden of NCDs in the Asia-Pacific region.
A Comprehensive Toxicity and Efficacy Analysis of Different Bridging Therapies Prior to Anti CD19-CAR-T Cell Therapy in Patients with DLBCL- a National Multi-Center Cohort Study
Authors: Ron Ram, Sigal Grisariu, Liat Shargian-Alon, Dana Yehudai-Ofir, Irit Avivi, Orit Gutfeld, Polina Stepensky, Tsila Zuckerman, Moshe Yeshurun, Odelia Amit, Batia Avni, Ronit Gurion, Yael Bar-On, Ofrat Beyar-Katz, Ronit Gold, Shimrit Ringelstein, Itai Levi, Tzvi Porges, Chava Perry
Journal: Blood (2021)
Modulation of p53 transcriptional activity: Effects on staurosporine-induced apoptosis of wild type and mutated p53 epithelial cells
Authors: J. F. Charlot, M. Nicolier, J. Y. Cahn, J. L. Pretet, C. Mougin
Journal: Cancer Research (2005)

2685  In most cancers p53 is inactivated by mutation or by viral oncoproteins such as E6 from high risk human papillomavirus (HPV), leading to apoptosis inhibition. However, a novel chemotherapeutic agent, named PRIMA-1 (p53 reactivation and induction of massive apoptosis), has been recently discovered to restore the transcriptional activity of mutant p53. Nevertheless, the role of p53 is not limited to its involvement in killing tumour cells. This protein is indeed highly expressed in several normal tissues damaged by anti-cancer therapy. Thus Pifithrin-α (p fifty-three inhibitor), a chemical inhibitor of p53, has been proposed to be used as an adjunct of chemotherapy in tumors lacking functional p53 to avoid damages of healthy neighborhoods’ tissues. In a recent publication (Apoptosis. 2004 9(3):333–43), we argued for a major role of p53 in staurosporine (ST)-induced apoptosis of immortalized epithelial cells, depending on their p53 status. Indeed, we found that wild-type p53 cells (HeLa HPV18+ and CaSki HPV16+ cells) were more sensitive to ST-induced mitochondrial membrane potential dissipation (-ΔΨm) and subsequent DNA fragmentation than cells harboring a mutated p53 without transcriptional activity (C33A cells). Recently, we were interested to test PRIMA-1 and Pifithrin-α (in addition to ST) to respectively restore or inhibit the p53 transcriptional activity in the different cell lines. The modulation of p53 transcriptional activity was monitored by western-blotting p53 targets (i.e. p21 and Bax). As expected, PRIMA-1 does not modify the percentage of HeLa and CaSki cells with -ΔΨm and DNA cleavage, whilst it increases by 45% apoptosis of C33A cells. As for Pifithrin-α, it does not modify the apoptosis level of C33A cells, but readily inhibits both -ΔΨm and DNA fragmentation of wild-type p53 cells. These data support the evidence that PRIMA-1 could be a good candidate, as an anti-cancer drug targeting mutant p53, in order to increase ST efficiency. Moreover, Pifithrin-α could be used in combination with ST and PRIMA-1 to prevent side effects of anti-tumor therapies. However, the use of both PRIMA-1 and Pifithrin-α must be strictly restricted to p53 transcriptionally defective tumors. In vivo experiments are ongoing to investigate the effects of these compounds in animal models and to establish the efficacy of this promising tritherapy on tumor growth inhibition.
Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis
Authors: Stella Talic, Shivangi Shah, Holly Wild, Danijela Gasevic, Ashika Maharaj, Zanfina Ademi, Xue Li, Wei Xu, Ines Mesa-Eguiagaray, Jasmin Rostron, Evropi Theodoratou, Xiaomeng Zhang, Ashmika Motee, Danny Liew, Dragan Ilic
Journal: BMJ (2021)

To review the evidence on the effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality.
Abstract 8912: The Ceramide- and Phosphatidylcholine- Based Coronary Event Risk Test2 (CERT2) and Cardiovascular Mortality in Men and Women with Type 2 Diabetes
Authors: Andreas Leiherer, Axel Muendlein, Christoph H Saely, Barbara Larcher, Arthur Mader, Maximilian Maechler, Lukas Sprenger, Beatrix Mutschlechner, Magdalena Benda, Reijo Laaksonen, Mitja Laaperi, Antti Jylha, Peter Fraunberger, Heinz Drexel
Journal: Circulation (2021)

Introduction: The recently introduced Coronary Event Risk Test version 2 (CERT2) is a validated cardiovascular risk predictor score that uses circulating ceramide and phosphatidylcholine concentrations. Hypothesis: We hypothesize that CERT2 hat the power to predict cardiovascular mortality in patients with type 2 diabetes (T2DM). Methods: Prospectively, out of 280 male and 121 female patients with T2DM we recorded 55 cardiovascular deaths in men and 19 in women during a mean follow-up time of 7.6±3.6 and 8.1±3.4 years respectively. Results: Overall, cardiovascular survival decreased with increasing CERT2 risk categories (figure 1). In Cox regression models, CERT2 significantly predicted the incidence of cardiovascular mortality in male patients with T2DM (unadj. HR 1.82 [1.39-2.37] per standard deviation; p&lt;0.001), the unadj. HR in women was 1.36 [0.83-2.22]; p=0.228). After adjustment for age, BMI, current smoking, LDL cholesterol, HDL cholesterol, hypertension, and statin use the HR in men was 1.73 [1.31-2.29]; p&lt;0.001) and in 1.40 [083-2.36]; p=0.210 women. Interaction terms CERT2 x gender were non-significant both in univariate analysis (p=0.354) and after multivariate adjustment (p=0.359). Conclusions: We conclude that sex does not significantly impact the association of CERT2 with cardiovascular mortality in patients with T2DM.
Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints
Authors: Juan-José Garcés, Noemi Puig, Rosalinda Termini, María Teresa Cedena, Cristina Moreno, José J Pérez, Diego Alignani, Sarvide Sarai, Albert Oriol, Esther González Garcia, Fernando Escalante, Anna Sureda, Felipe De Arriba, Rafael Rios, Jose Maria Moraleda, Mercedes Gironella, Miguel T Hernández, Juan Jose Joan Bargay, Luis Palomera, Alberto Orfao, Evangelos Terpos, Albert Pérez, Tomas Jelinek, Alexia Suárez, Hartmut Goldschmidt, Hervé Avet-Loiseau, Aldo M. Roccaro, Joaquin Martinez-Lopez, Juan Jose Lahuerta, Enrique Ocio, Laura Rosinol, Joan Bladé Creixenti, Maria-Victoria Mateos, Jesus San-Miguel, Bruno Paiva
Journal: Blood (2021)
Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study
Authors: Takaaki Ono, Masayuki Hino, Itaru Matsumura, Shin Fujisawa, Kenichi Ishizawa, Emiko Sakaida, Naohiro Sekiguchi, Chiho Ono, Mana Aizawa, Yusuke Tanetsugu, Yuichiro Koide, Naoto Takahashi
Journal: Blood (2021)
Abstract 9511: Implication of the KATP SUR2B/kir6.1 in the Physiopathology of Pulmonary Arterial Hypertension
Authors: Helene Le Ribeuz, Mary Dutheil, veronique capuano, Olaf M Mercier, Marc Humbert, David Montani, Fabrice Antigny
Journal: Circulation (2021)

Introduction: PAH is a severe and rare cardiopulmonary disease which is defined by an elevation of the mean pulmonary artery pressure &gt;25mmHg. ABCC9 mutations are responsible of Cantu syndrome, a disease characterised by several cardiac disorders and for some case pulmonary hypertension (PH). ABCC9 gene encodes for SUR2 protein, a regulatory subunit of KATP channels. KATP are composed of SUR1 or SUR2 and Kir6.1 or Kir6.2 subunits. We hypothesized that SUR2 / Kir6.1 channel contributes to PAH pathogenesis and could be a therapeutic target against PAH. Methods: Using a combination of in vitro , ex vivo and in vivo approaches, we analysed the localisation and expression of SUR2A, SUR2B and Kir6.1 in pulmonary vasculature from control and PAH patients as well as in experimental PH rat-models. We also analysed the role of SUR2/Kir6.1 in PAH physiopathology (PASMCs proliferation, migration and contraction). Finally, we deciphered the consequences of in vivo pharmacological activation of SUR2/Kir6.1 in experimental model of PH. Results: We demonstrated that SUR2A, SUR2B and Kir6.1 are expressed (mRNA and protein) in lungs from control and PAH patients and in MCT induced-PH model.Myograph experiments demonstrated that pharmacological activation of SUR2 by pinacidil induced pulmonary arterial relaxation in human and rat isolated pulmonary arteries. PA relaxation was still present in PA from MCT-rats but reduced compared to control rats. In vitro experiments on human PASMCs (hPASMCs) from control and PAH patients show a decrease of the cell proliferation and migration after SUR2 activation (pinacidil). Using Patch-clamp technique, we demonstrated that SUR2 activator (pinacidil) in adult rat RV cardiomyocytes reduces RV action potential. Finally, pharmacological activation in vivo of SUR2 by pinacidil (1mg/kg/day) on MCT induced-PH rats show an improvement of the hemodynamic parameters as the mean right ventricular systolic pressure during preventive and curative protocol. Conclusions: We demonstrated that SUR2A, SUR2B and Kir6.1 are expressed in hPASMCs and hPECs from control and iPAH patients. The in vivo SUR2 activation by pinacidil treatment reduced MCT induced-PH phenotype suggesting that SUR2 pharmacological activation should be considered for PAH.
Robust thrombolytic and anti-inflammatory action of a constitutively active ADAMTS13 variant in murine stroke models
Authors: Kieron South, Ohud Saleh, Eloise Lemarchand, Graham Coutts, Craig J. Smith, Ingo Schiessl, Stuart M. Allan
Journal: Blood (2021)

Advances in our understanding of ADAMTS13 structure, and the conformation changes required for full activity, have rejuvenated the possibility of its use as a thrombolytic therapy. We have tested a novel Ala1144Val ADAMTS13 variant (constitutively active [ca] ADAMTS13) that exhibits constitutive activity, characterized using in vitro assays of ADAMTS13 activity, and greatly enhanced thrombolytic activity in 2 murine models of ischemic stroke, the distal FeCl3 middle cerebral artery occlusion (MCAo) model and transient middle cerebral artery occlusion (tMCAO) with systemic inflammation and ischemia/reperfusion injury. The primary measure of efficacy in both models was restoration of regional cerebral blood flow (rCBF) to the MCA territory, which was determined using laser speckle contrast imaging. The caADAMTS13 variant exhibited a constitutively active conformation and a fivefold enhanced activity against fluorescence resonance energy transfer substrate von Willebrand factor 73 (FRETS-VWF73) compared with wild-type (wt) ADAMTS13. Moreover, caADAMTS13 inhibited VWF-mediated platelet capture at subphysiological concentrations and enhanced t-PA/plasmin lysis of fibrin(ogen), neither of which were observed with wtADAMTS13. Significant restoration of rCBF and reduced lesion volume was observed in animals treated with caADAMTS13. When administered 1 hour after FeCl3 MCAo, the caADAMTS13 variant significantly reduced residual VWF and fibrin deposits in the MCA, platelet aggregate formation, and neutrophil recruitment. When administered 4 hours after reperfusion in the tMCAo model, the caADAMTS13 variant induced a significant dissolution of platelet aggregates and a reduction in the resulting tissue hypoperfusion. The caADAMTS13 variant represents a potentially viable therapeutic option for the treatment of acute ischemic stroke, among other thrombotic indications, due to its enhanced in vitro and in vivo activities that result from its constitutively active conformation.
Results of Hematopoietic Stem Cells Transplantation with Tcrαβ and CD19-Depletion from Matched Related Donors and Infusions of CD45RA Depleted Donor Lymphocytes in Pediatric Severe Aplastic Anemia
Authors: Larisa Shelikhova, Anna Bogoyavlenskaya, Maria Ilushina, Tatiana Salimova, Kristina Antonova, Julia Skvortsova, Daria Shasheleva, Svetlana Radygina, Elvira Sultanova, Svetlana Glushkova, Ruslan Nikolaev, Elena Kurnikova, Dmitry Pershin, Yakov Muzalevsky, Alexey Kazachenok, Elena Osipova, Dmitriy Balashov, Galina Novichkova, Alexey Maschan, Michael Maschan
Journal: Blood (2021)
Prognostic Role of IL-6 in POEMS Syndrome
Authors: Maryam Omar, Rahma M Warsame, Morie A. Gertz, Francis K. Buadi, Ronald Go, Shaji Kumar, David Dingli, Robert A. Kyle, Nelson Leung, Taxiarchis Kourelis, Suzanne R. Hayman, Yi Lin, Martha Q. Lacy, John A. Lust, Yi L. Hwa, Amie Fonder, Prashant Kapoor, Miriam A. Hobbs, Wilson I Gonsalves, S. Vincent Rajkumar, Eli Muchtar, Alissa Visram, Stephen J. Russell, Angela Dispenzieri
Journal: Blood (2021)
ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing
Authors: Lazaros J. Lekakis, Frederick L. Locke, Michael Tees, Sattva S. Neelapu, Shahbaz A. Malik, Mehdi Hamadani, Matthew J. Frank, Leslie L. Popplewell, Jeremy S. Abramson, Sven de Vos, Javier Munoz, Chu Ri Shin, Arun Balakumaran, Lynn Loomis-Navale, Lovely Goyal, Xiangdong Zhou, David B. Miklos
Journal: Blood (2021)
Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data
Authors: Srdan Verstovsek, Mohamed E Salama, John Mascarenhas, Moshe Talpaz, Ruben A. Mesa, Alessandro Vannucchi, Raajit Rampal, Stephen T. Oh, Horatiu Olteanu, April Chiu, Dong Chen, Curtis A. Hanson, Natalia Curto-Garcia, Pietro Taverna, Jike Cui, Oksana Zavidij, Zehua Chen, Gozde Colak, Sergey Efuni, Patricia J Keller, Patrick Trojer, Claire N. Harrison
Journal: Blood (2021)
Abstract 12515: Comparison in Hemocompatibility-Related Adverse Events in Patients Supported With Left Ventricular Assist Device Between Japan and United States
Authors: Teruhiko Imamura, Minoru Ono, Norihide Fukushima, Koichiro Kinugawa, Akira Shiose, Yoshiro Marsui, Kenji Yamazaki, Yoshikatsu Saiki, Akihiko Usui, Hiroshi Niinami, Goro Matsumiya, Hirokuni Arai, Yoshiki Sawa, Gene Kim, Gabriel Sayer, Yoshifumi Naka, Valluvan Jeevanandam, Nir Uriel
Journal: Circulation (2018)

Background: Clinical outcomes of left ventricular assist device (LVAD) therapy are reported, but may be different between the countries. This study aimed to compare hemocompatibility-related advers...
IMMU-46. ARTIFICIAL INTELLIGENCE-DIRECTED, GENE THERAPY-BASED TRANSDIFFERENTIATION OF GLIOBLASTOMA TO FUNCTIONAL DENDRITIC CELLS AS NOVEL CANCER IMMUNOTHERAPY
Authors: Dan Jin, Son Le, Mathew Sebastian, Dongjiang Chen, Linchun Jin, David Tran
Journal: Neuro-Oncology (2021)

Abstract BACKGROUND Despite recent advances in tumor immunotherapy in solid tumors, success in GBM remains elusive, likely due to its poor immunogenicity and CNS barriers limiting immune cell trafficking. Here we describe a novel approach of stimulating glioma-specific immunity by transdifferentiating GBM cells in situ to induced dendritic cells (iDCs). METHODS We applied NETZEN, an integrated deep-learning and gene network-based ranking computational platform and identified cell fate determinants (CFDs) to convert GBM cells to DCs. CFDs were delivered using a viral vector. Transdifferentiation was assessed by immunophenotyping and iDCs functionally validated by their ability to prime naive T cells. RESULTS A four CFDs subnetwork anchored by PU.1 was sufficient to transdifferentiate mouse GBM cells to CD45+MHCII+ cells with high co-stimulatory CD80 expression and to induce nearly 98% of GBM cells to express 100-fold higher levels of MHCI. Consistent with a new identity of antigen-presenting cells (APC), the induced immune cells are growth arrested, exhibit 3-fold higher phagocytic activity and upregulate the canonical antigen processing and presenting machineries by 10-40 folds, resulting in 40-fold greater efficiency at processing ovalbumin and presenting SIINFEKL on MHCI compared to native GBM cells. Importantly, SIINFEKL-loaded iAPCs are capable of activating naive OTII-CD4+ and OTI-CD8+ T cells, indicating that they are DC-like. In addition, iDCs efficiently present tumor cell-intrinsic antigens and elicit &amp;gt;20-fold higher activation and cytotoxicity in tumor-specific T cells compared to native GBM cells. Lastly, intratumoral GBM-DC transdifferentiation in a syngeneic orthotopic GBM model produces a robust memory T cell response in deep cervical draining lymph nodes compared to control animals. CONCLUSIONS Our results comfirm that GBM-derived iDCs acquire functions similar to native DCs, and thus, lay the foundation for a novel therapeutic approach in which poorly immunogenic tumors like GBM may be forced to generate their own immunity from within through cell fate transdifferentiation.
Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121)
Authors: Michel Delforge, Nina Shah, Paula Rodríguez-Otero, Julia Braverman, Devender Dhanda, Ling Shi, Shien Guo, Peiwen Yu, Weiqin Liao, Timothy B. Campbell, Nikhil C. Munshi
Journal: Blood (2021)
CD20-Specific Chimeric Antigen Receptor-Expressing T Cells As Salvage Therapy in Rituximab-Refractory CD20(+) B-Cell Non-Hodgkin Lymphoma
Authors: Xin Li, Qian Cheng, Rui Liu, Liqing Kang, Nan Xu, Minghao Li, Lei Yu
Journal: Blood (2021)
SAGO has a politics problem, and WHO is ignoring it
Authors: Joshua Moon, Clare Wenham, Sophie Harman
Journal: BMJ (2021)

The World Health Organisation’s (WHO) Scientific Advisory Group on the Origins of Novel Pathogens (SAGO) has recently been established to “define and guide studies into the origins [of Novel Pathogens]” and “advise WHO on prioritising studies and field investigations into [Novel Pathogens].” In both of these, an attention to political questions like “which pathogens deserve investigation?” and “how should countries’ possible pathogen origins be prioritised?” will need to be addressed.

However, arguments have been made by WHO that SAGO should “follow the science” and “avoid politicisation.”1 There is a clear tension here. The statement to “avoid politicisation” is a political act in itself. It is an act that suggests states, government, and citizens have no business in holding science to account. In turn it is an act that both recognises the role and importance of politics, but sees the answer as doing nothing about it. Politics is framed as a problem—a major stumbling block to both pandemic preparedness and response, and for science to do its work—but one best avoided rather than understood. Political expertise is reduced to the important work of diplomacy or political communication. There is also an assumption that all political engagement means partisan or geo-politics, which is a misnomer. Politics is located at all levels, from the micropolitics of the Wuhan laboratory to the geopolitics of the G7 and UN systems. The publication of the membership of SAGO shows a lack of attention to expertise in the social sciences, and politics in particular.2 This is sure to …
Fc-Mediated Complement Activation Is Associated with Macrophage Trafficking and Induction of Neutrophil Extracellular Traps in Transfusion-Related Acute Lung Injury
Authors: Saskia van der Velden, Thijs L.J. van Osch, Amina Seghier, Arthur Bentlage, Juk Yee Mok, Dionne M Geerdes, Wim J.E. van Esch, Masja De Haas, Leendert Porcelijn, C. Ellen van der Schoot, Gestur Vidarsson, Rick Kapur
Journal: Blood (2021)
Screening for antimicrobial-resistant Gram-negative bacteria in hospitalised patients, and risk of progression from colonisation to infection: Systematic review
Authors: Guglielmo Arzilli, Giuditta Scardina, Virginia Casigliani, Davide Petri, Andrea Porretta, Marco Moi, Ersilia Lucenteforte, Jordi Rello, Pierluigi Lopalco, Angelo Baggiani, Gaetano Pierpaolo Privitera, Lara Tavoschi
Journal: Journal of Infection (2021)
Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial
Authors: Robert F. Sidonio, Christine Knoll, Flora Peyvandi, Oleksandra Stasyshyn, Ali Bulent Antmen, Seoh Leng Yeoh, Darintr Sosothikul, Caterina Maggiore, Werner Engl, Geoffrey Allen, Srilatha Tangada
Journal: Blood (2021)
Umbilical Cord Blood Microtransplantation in Newly Diagnosed, Elderly Patients with Acute Myeloid Leukemia
Authors: Wen Yao, Liangquan Geng, Dongyao Wang, Huilan Liu, Baolin Tang, Guangyu Sun, Ping Qiang, Xiang Wan, Yongsheng Han, Zimin Sun
Journal: Blood (2021)
Outcomes with Interferon in Essential Thrombocythemia: A Systematic Review and Meta-Analysis
Authors: Moazzam Shahzad, Mamoon Ahmed, Sakina Abbas, Muhammad Arslan, Tooba Kashif, Iqra Anwar, Ali Hussain, Qamar Iqbal, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Joseph P. McGuirk, Muhammad Umair Mushtaq, Abdulraheem Yacoub
Journal: Blood (2021)
Whole Blood Adhesion to VCAM-1 and P-Selectin and RBC Mechanical Fragility Can be Compromised in Long COVID-19 Patients with Sickle Cell Disease
Authors: Michael Tarasev, Marta Ferranti, Cidney Allen, Xiufeng Gao, Kayla Topping, Marta Ferranti, Biola Makinde-Odesola, Lanetta Bronté-Hall, Patrick Hines
Journal: Blood (2021)